GlassScriptPhysician profile
Jorge R Minera
NPI 1750389987
$1,163.68
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $345 · 2020: $25.22 · 2021: $229 · 2022: $114 · 2023: $350 · 2024: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $450.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $197.73 | 2019-2023 | Wegovy |
| Intra-Sana Laboratories | $159.19 | 2023 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Supernus Pharmaceuticals, INC. | $124.98 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $80.96 | 2019 | |
| Vivus LLC | $78.61 | 2024 | Qsymia |
| Rhythm Pharmaceuticals, INC. | $73.94 | 2022-2023 | Imcivree |
| Takeda Pharmaceuticals U.S.A., INC. | $70.14 | 2019-2022 | |
| Amgen INC. | $68.66 | 2019-2021 | |
| Currax Pharmaceuticals LLC | $45.32 | 2021-2023 | Contrave |
| Clarus Therapeutics INC. | $39.68 | 2021 | |
| Lilly USA, LLC | $35.58 | 2019-2024 | Zepbound, Jardiance |
| Abbvie INC. | $32.24 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $23.52 | 2019-2020 | |
| Antares Pharma, INC. | $21.51 | 2022 | |
| Pfizer INC. | $18.31 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $17.97 | 2021 | |
| Sanofi-Aventis U.S. LLC | $15.78 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $14.79 | 2019 | |
| Gilead Sciences, INC. | $14.67 | 2019 | |
| Merck Sharp & Dohme LLC | $12.07 | 2021 | |
| Alkermes, INC. | $10.85 | 2019 | |
| Kvk-Tech, INC. | $7.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Minera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.